You are here: Home: Audio Program Guide: CCU Nurses 1 2007: CCU Nurses 1 2007 Audio
 
 

Go to interview with Axel Grothey, MD
Go to interview with Nina Grenon, MS, APRN-BC, AOCN
Go to interview with Daniel G Haller, MD
Go to interview with Mr S
Go to interview with Ms R
Go to interview with Margot F Sweed, CRNP


  To listen to individual tracks, click the on the headphone.
To download tracks, right-click on the one you wish to download.
Grothey, MD Axel Grothey, MD
Senior Associate Consultant
Department of Medical Oncology
Mayo Clinic
Rochester, Minnesota
  
  Click here to download the entire interview  
Track 1 Factors considered when deciding on adjuvant therapy for early colorectal cancer
Track 2 Correlation between the number of lymph nodes examined and risk of recurrence
Track 3 Selection of a chemotherapy regimen in the adjuvant setting
Track 4 Side effects associated with FOLFOX
Track 5 Neurotoxicity secondary to oxaliplatin
Track 6 Use of calcium and magnesium to prevent oxaliplatin-induced neuropathy
Track 7 Recent data from the CONcePT study demonstrating less antitumor effect secondary to calcium and magnesium
Track 8 Bevacizumab as treatment for metastatic colorectal cancer
Track 9 Side effects of bevacizumab
Track 10 Mechanisms of action of bevacizumab
Track 11 Evolution of the BRiTE Tumor Registry
Track 12 iBET trial evaluating continuation of bevacizumab after disease progression
Track 13 Efficacy and toxicity of bevacizumab in the adjuvant setting
     
Grenon, MD Nina Grenon, MS, APRN-BC, AOCN
Adult/Geriatric Nurse Practitioner
Center for Gastrointestinal Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts
  
  Click here to download the entire interview  
Track 1 Oxaliplatin-related laryngopharyngeal dysesthesia
Track 2 Delayed peripheral neuropathy secondary to oxaliplatin
Track 3 Impact of the CONcePT study data on the prophylactic use of calcium and magnesium
Track 4 Factors influencing patients’ interest in adjuvant therapy
Track 5 Adjuvant therapy for elderly patients
Track 6 Clinical trial evaluating adjuvant FOLFOX with or without cetuximab
Track 7 Tolerability of bevacizumab
Track 8 Reversible posterior leukoencephalopathy (RPLE) and bevacizumab
Track 9 Differential diagnosis and symptoms of RPLE
Track 10 Overall survival of patients with metastatic colorectal cancer
Track 11 Excision of liver metastases with curative intent
Track 12 Quality of life for patients with metastatic disease
     
Haller, MD Daniel G Haller, MD
Professor of Medicine
Abramson Cancer Center
at the University of Pennsylvania
Philadelphia, Pennsylvania
  
  Click here to download the entire interview  
Track 1 Relationship between the number of lymph nodes examined and the risk of recurrence
Track 2 Risk factors in Stage II colorectal cancer
Track 3 Patient expectations regarding the side effects of chemotherapy
Track 4 Educating patients on peripheral neuropathy secondary to oxaliplatin
Track 5 Patient education regarding oxaliplatin-related cold sensitivity and laryngopharyngeal dysesthesia
Track 6 Management of peripheral neuropathy
Track 7 Risk of residual neuropathy secondary to oxaliplatin
Track 8 Clinical trials of adjuvant FOLFOX with or without bevacizumab
Track 9 Risk of bowel perforation for patients on bevacizumab
Track 10 Risk of bevacizumab-related vascular thrombotic events and wound-healing impairment
Track 11 Hypertension related to bevacizumab
     
  Mr S

  
  Click here to download the entire interview  
Track 1 Retired schoolteacher diagnosed with colorectal cancer with a history of chemotherapy for sarcoma
Track 2 Patient’s experience with chemotherapy
Track 3 Neurotoxicity secondary to oxaliplatin
Track 4 Quality of life three years after adjuvant chemotherapy
Track 5 Patient’s perspective on the impact of a cancer diagnosis
     
  Ms R
  
  Click here to download the entire interview  
Track 1 Impact of systemic therapy on quality of life
Track 2 Cancer diagnosis and change in life perspective
Track 3 Living with metastatic colorectal cancer
     
Sweed, CRNP Margot F Sweed, CRNP
Nurse Practitioner
GI Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania
  
  Click here to download the entire interview  
Track 1 Counseling patients on the risk and management of laryngopharyngeal dysesthesia
Track 2 Educating patients on the side effects of FOLFOX
Track 3 Risk factors for patients with Stage II disease